Little Journey, the innovative healthtech company transforming the delivery of paediatric care through personalised psychological support, today announced £6 million in Series A funding. The round, which will be used to accelerate Little Journey's mission to revolutionise paediatric healthcare globally, was led by Edinburgh and Leeds-based venture capital firm Par Equity. Additional investment was made by Mercia Ventures, the Northern Powerhouse Investment Fund I, Octopus Ventures, Calm/Storm Ventures, and angel investors with expertise in healthcare and life sciences.
The funding will be used to scale Little Journey's operations globally with a focus on the US healthcare market. With early adopters already in place, Little Journey aims to continue expansion into this key market to extend its transformative support to more children and families worldwide.
The investment will also fund product enhancements, including the development of its scalable content plus interoperability and data collection capabilities. These advancements will enable healthcare and life science organisations to adopt more data-focused, patient-centric approaches to care and decision-making, ultimately improving outcomes for paediatric patients globally.
The funding will also support the maturation of Little Journey's systems, ensuring the company's infrastructure and product security are robust and scalable for global adoption.
Securing this investment allows us to scale our impact across healthcare and life sciences, with a focus on easing the burden of paediatric clinical trials. While legislation like RACE, SPCs, and the ODA has increased study numbers, specialist paediatric knowledge is still lacking in the industry. This has led to lower recruitment, adherence and trial completion rates compared to adult research. Little Journey is uniquely positioned to fill this expertise gap and tackle these challenges to advance global paediatric medicine. With the backing of Par Equity, Mercia Ventures, Octopus Ventures, and our wider investor network, we’re redefining how paediatric clinical trials are run and putting families at the heart of them.
Chris Evans, Co-founder & CEO
We’re ready to take our product capabilities to the next level. Little Journey already tailors support based on age, language, procedure, and trial protocol. With this Series A funding, we will enhance our data capabilities and further globalise our offering, enabling a data-driven, personalised model of care in paediatrics. This will drive impact for our growing international customer base in a patient-centric way. By empowering families with the right knowledge and resources at the right time, we believe we can help build a brighter, healthier future for all children across the globe.
Sophie Copley, Co-founder & CPO
Healthtech is at the heart of what we do at Par Equity. We are committed to supporting high-growth, impactful health tech companies that have the potential to revolutionise the way that care is delivered. At present, there exists a pressing need for bespoke technologies tailored to children and Little Journey’s innovative approach to paediatric care does just that. We look forward to seeing what’s in store for the future of children’s healthcare and are excited to support Little Journey’s expansion into the US and beyond.
Elizabeth Young, Investment Manager at Par Equity
